Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-10-29
DOI
10.1002/cncr.32547
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma
- (2019) D. Viñal et al. Clinical & Translational Oncology
- Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
- (2019) Zeynep Eroglu et al. Pigment Cell & Melanoma Research
- Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
- (2018) Sara Valpione et al. EUROPEAN JOURNAL OF CANCER
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases
- (2018) Joshua Z. Drago et al. MELANOMA RESEARCH
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
- (2017) Jonas Cicenas et al. MEDICAL ONCOLOGY
- BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response
- (2017) Céline Desvignes et al. MELANOMA RESEARCH
- Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening
- (2016) Ying I. Wang et al. BIOTECHNOLOGY AND BIOENGINEERING
- Melanoma central nervous system metastases: current approaches, challenges, and opportunities
- (2016) Justine V. Cohen et al. Pigment Cell & Melanoma Research
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma
- (2015) Jennifer Roux et al. MELANOMA RESEARCH
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Management of Multiple Melanoma Brain Metastases
- (2015) Sharad Goyal et al. JAMA Oncology
- The malignant melanoma landscape
- (2014) Rachel M. Webster et al. NATURE REVIEWS DRUG DISCOVERY
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
- (2013) Reinhard Dummer et al. EUROPEAN JOURNAL OF CANCER
- Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer
- (2013) Saurabh Ray et al. JOURNAL OF NEURO-ONCOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
- (2012) Amélie Clémentine Seghers et al. MELANOMA RESEARCH
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Prognostic factors for survival in melanoma patients with brain metastases
- (2010) Michael A. Davies et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started